iScience · 2023 · 10 citations · 39 references
MedicineMolecular MedicineOncologyCancer PharmacologyMolecular OncologyOncogenesDrug ResistanceReceptor Tyrosine Kinase OncogenesTargeted Cancer TherapyTargeted TherapyTherapeutic ResistanceTyrosine Kinase InhibitorsAmplificationIn Vivo Resistance AssaysKinase Inhibitor ResistanceMet InhibitorsMet-targeted TherapyProtein Kinase InhibitorsResistance To Targeted TherapyTherapeutic Resistance Mechanisms
This study evaluates the efficacy of combining targeted therapies with MET or SHP2 inhibitors to overcome MET-mediated resistance in different NSCLC subtypes. A prevalence study was conducted for MET amplification and overexpression in samples from patients with NSCLC who relapsed on ALK, ROS1, or RET tyrosine kinase inhibitors. MET-mediated resistance was detected in 37.5% of tissue biopsies, which allow the detection of MET overexpression, compared to 7.4% of liquid biopsies. The development of drug resistance by MET overexpression was confirmed in EGFR ex19del -, KRAS G12C -, HER2 ex20ins -, and TPM3-NTRK1 -mutant cell lines. The combination of targeted therapy with MET or SHP2 inhibitors was found to overcome MET-mediated resistance in both in vitro and in vivo assays. This study highlights the importance of considering MET overexpression as a resistance driver to NSCLC targeted therapies to better identify patients who could potentially benefit from combination approaches with MET or SHP2 inhibitors.
39
<i>EGFR</i> Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
J. Guillermo Paez, Pasi A. Jänne, Jeffrey C. Lee et al. · Science · 2004 · 9.4K citations
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
Alice T. Shaw, Dong‐Wan Kim, Kazuhiko Nakagawa et al. · New England Journal of Medicine · 2013 · 3.4K citations · Full text
Medicine, Oncology, Pharmacology +15
Acquired Resistance to KRAS <sup>G12C</sup> Inhibition in Cancer
New England Journal of Medicine · 2021 · 1.2K citations · Full text